Noopur Raje, MD

Articles by Noopur Raje, MD

CAR-T Therapies Therapy in RRMM

ByNoopur Raje, MD,Jacob Laubach, MD,Omar Nadeem, MD,Andrew J. Yee, MD

July 11th 2022

A brief review of the use of CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Patient Profile 3: A 57-Year-Old Woman With Triple-Class Refractory MM

ByNoopur Raje, MD,Jacob Laubach, MD,Omar Nadeem, MD,Andrew J. Yee, MD

July 6th 2022

Moving to the last patient profile, expert panelists discuss a patient with triple-class refractory multiple myeloma managed with BCMA-targeting bispecific therapy.

Treating Transplant-Ineligible NDMM With High-Risk Cytogenetics

ByNoopur Raje, MD,Jacob Laubach, MD,Omar Nadeem, MD,Andrew J. Yee, MD

July 6th 2022

Shared insight on the selection of therapy for patients with transplant-ineligible, newly diagnosed multiple myeloma and high-risk cytogenetics.

Selection and Duration of Therapy in Transplant-Ineligible NDMM

ByNoopur Raje, MD,Jacob Laubach, MD,Omar Nadeem, MD,Andrew J. Yee, MD

June 29th 2022

Expert panelists consider which regimen they would use, and for what duration, in the setting of transplant-ineligible, newly diagnosed multiple myeloma.

Patient Profile 2: A 72-Year-Old With Transplant-Ineligible NDMM

ByNoopur Raje, MD,Jacob Laubach, MD,Omar Nadeem, MD,Andrew J. Yee, MD

June 29th 2022

The panel moves on to review the profile of a patient with transplant-ineligible, newly diagnosed multiple myeloma managed with dara-Rd on the MAIA trial.

Duration of Therapy in NDMM

ByNoopur Raje, MD,Jacob Laubach, MD,Omar Nadeem, MD,Andrew J. Yee, MD

June 22nd 2022

Before closing their discussion on transplant-eligible, newly diagnosed multiple myeloma, experts consider duration of therapy in this setting.

Selecting Appropriate Therapy for Transplant-Eligible NDMM

ByNoopur Raje, MD,Jacob Laubach, MD,Omar Nadeem, MD,Andrew J. Yee, MD

June 22nd 2022

Panelists briefly review factors they use to select induction therapy for patients with transplant-eligible, newly diagnosed multiple myeloma.

Quadruplet Vs Triplet Induction Regimens for Transplant-Eligible NDMM

ByNoopur Raje, MD,Jacob Laubach, MD,Omar Nadeem, MD,Andrew J. Yee, MD

June 15th 2022

Shared insight on approved quadruplet vs triplet induction regimens for patients with transplant-eligible, newly diagnosed multiple myeloma, evaluated in the GRIFFIN, MASTER and GMMG-HD7 trials.